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The contributions of the humoral immune response to melanoma are now widely 
recognised, with reports of positive prognostic value ascribed to tumour-infiltrating B 
cells (TIL-B) and increasing evidence of B cells as key predictors of patient response 
to treatment. There are disparate views as to the pro- and anti-tumour roles of B 
cells. B cells appear to play an integral role in forming tumour-associated tertiary 
lymphoid structures (TLS) which can further modulate T cell activation. Expressed 
antibodies may distinctly influence tumour regulation in the tumour 
microenvironment, with some isotypes associated with strong anti-tumour immune 
response and others with progressive disease. Recently, B cells have been 
evaluated in the context of cancer immunotherapy. Checkpoint inhibitors (CPI), 
targeting T cell effector functions, have revolutionised the management of melanoma 
for many patients, however, there remains a need to accurately predict treatment 
responders. Increasing evidence suggests that B cells may not be simple bystanders 
to CPI immunotherapy. Mature and differentiated B cell phenotypes are key positive 
correlates of CPI response. Recent evidence also points to an enrichment in 
activatory B cell phenotypes and the contribution of B cells to TLS formation may 
facilitate induction of T cell phenotypes required for response to CPI. Contrastingly, 
specific B cell subsets often correlate with immune-related adverse events (irAEs) in 
CPI. With increased appreciation of the multifaceted role of B cell immunity, novel 
therapeutic strategies and biomarkers can be explored and translated into the clinic 




During early stages, primary melanoma lesions are removable through surgical 
intervention that is largely curative. In advanced disease however, melanoma can 
spread to regional lymph nodes and metastasise to distant sites. Historically 
treatment options were limited in advanced disease to palliative cytotoxic 
chemotherapy, leading to poor 5-year survival rates. Over the last decade 
immunotherapy, driven by checkpoint inhibitor antibodies, has transformed patient 
prognosis.  
 
The rationale behind the use of checkpoint inhibitor therapy lies in the highly 
immunogenic nature of melanoma (1,2). Melanoma carries a large mutational load, 
providing a range of tumour-specific antigens that are thought to elicit a host immune 
response. However, melanoma cells can evade immunosurveillance via activation of 
different immune-inhibitory pathways, including via immune checkpoint molecules 
and their downstream signals. Physiologically, checkpoint pathways play a role in 
immune homeostasis, providing negative feedback stimuli to prevent autoimmune 
reactivity. The best-studied checkpoint pathways are those of negative regulatory 
molecules cytotoxic T lymphocyte associated protein-4 (CTLA-4) and of the 
Programmed Death Receptor 1 (PD-1) and its ligands PD-L1 and PD-L2. 
 
Checkpoint inhibitors (CPI) were designed to promote immune-mediated elimination 
of tumour cells through modulation of T cell responses. Anti-CLTA-4 (Ipilimumab 
approved in 2011) (3) or anti-PD-1 (Pembrolizumab and Nivolumab approved in 
2014) (3,4) antibodies inhibit binding of checkpoint molecules with their respective 
ligand in the tumour microenvironment or draining lymph nodes. A newer anti-PD-L1 
agent, Atezolizumab, was approved by the FDA in July 2020 (5). CPI are approved 
for use as monotherapy in metastatic melanoma and as adjuvant therapy. More 
recently combination Nivolumab and Ipilimumab have been approved for metastatic 
disease in select patient groups. Their clinical efficacy and long-term outcomes are 
highlighted in the CheckMate 067 clinical trial (ClinicalTrials.gov NCT01844505) (4). 
In 945 patients with stage III or IV melanoma, this trial directly evaluated combination 
therapy with Nivolumab plus Ipilimumab in comparison with monotherapy with 
Nivolumab or with Ipilimumab. At a minimum follow-up of 60 months, the median 
overall survival (OS) was more than 60.0 months (median not reached) in the 
Nivolumab-plus-Ipilimumab group, 36.9 months in the Nivolumab group and 19.9 
months in the Ipilimumab group. The 5-year OS rates were 52%, 44%, and 26% 
respectively (4). 
 
Despite the undeniable clinical success of CPI therapy several challenges remain. 
There is currently a lack of biomarkers, limiting our ability to predict who will respond 
to treatment. Another important consideration is recognising who will develop 
toxicities, that are unfortunately common particularly with anti-CTLA-4 treatment and 
in the context of combination anti-CTLA-4 and anti-PD-1 therapy as compared with 
monotherapy. These toxicities, known as immune related adverse events (irAE) vary 
in severity, can affect any organ system but most commonly target the skin, the 
gastrointestinal and the endocrine systems (6). Although many of these toxicities are 
manageable/reversible they frequently lead to treatment disruption or 
discontinuation. Therefore, understanding the mechanisms underlying irAE and 
predicting these irAE is a much-needed clinical strategy.  
 
The role of T cells in CPI therapy has been extensively reviewed in literature. 
Contrastingly, B cell immunity has been less studied. B cells have a wide range of 
roles, including critical functions as professional antigen presenting cells (APCs) and 
they are capable of secreting cytokines and antibodies which enable them to conduct 
antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular 
phagocytosis (ADCP) and complement-dependent cytotoxicity (CDC). Considering 
their comprehensive functions and with B cells making up one of the two arms of the 
adaptive immune system, it is not surprising to envisage a role within melanoma 
immunity and response to CPI. However, the exact role B cells play in tumour 
immunity is unclear with the existence of different cell subsets with juxtaposing 
functions, such as activatory and regulatory B cells (Breg), and the presence of B 
cells in tertiary lymphoid structures (TLS). The potential pro- and anti-tumour roles of 
B cells in melanoma are summarised in Figure 1. In this review we discuss emerging 
evidence for the significance of B cell and antibody immune responses in melanoma 
and specifically in the context of CPI therapy. 
 
 
The CTLA-4 and PD-1 pathways  
 
CTLA-4 is an inhibitor of T cell activation primarily expressed on naïve T cells after 
activation (7–10)  and constitutively expressed on FoxP3+ regulatory T cells (Treg) 
(10). T cell activation is dependent not only T cell receptor (TCR) binding with an 
antigen presented via an APC, but also on the presence of a costimulatory second 
signal, typically through binding of CD28 on the T cell to CD80/86 on the APC. 
CTLA-4 is a competitive CD28 homolog that has a higher affinity to CD80 (B7-1), and 
to a lesser degree CD86 (B7-2) than CD28 therefore inhibiting T cell co-stimulation 
(10). TCR signalling up-regulates cell surface CTLA-4 expression, reaching peak 
expression at 2 to 3 days after activation (7,8). This provides a negative feedback 
loop for T cell activation.  
PD-1 is also a member of the immunoglobulin superfamily known to contribute to 
immune homeostatic processes by delivering inhibitory signals upon engagement 
with its ligands, programmed death ligands 1 and 2 (PD-L1/2). Like CTLA-4, PD-1 is 
thought to be a negative regulator of T cell function, regulating peripheral tolerance 
and T cell responses. PD-1 is expressed more broadly than CTLA-4 and can be 
found on T cells, B cells, natural killer (NK) cells and a variety of peripheral tissues 
(11). Expression of PD-1 is upregulated upon activation of T cells and B cells (12). 
The ligand PD-L1 is broadly expressed by immune cells including T cells, B cells, 
dendritic cells and macrophages, and in non-lymphoid tissues including on tumour 
cells or stromal elements in the tumour microenvironment (TME) (11,13). Recent 
evidence suggests that CD28 is also a primary target for PD-1 (14,15). 
Intracellularly, both PD-1 and CTLA-4 signal via SHP2 and converge to inhibit 
downstream P13K signalling (16,17). Although it is reported that B cells express PD-
1 and PD-L1, these cells have not been recognised as a primary target for anti-PD-1 
therapy. CTLA-4 also acts extracellularly to clear the CD28 ligands CD80/86 from 
surrounding cells, including APCs, by trans-endocytosis in vivo, further inhibiting T-
cell activation (18). While B cells are also known to express CTLA-4 ligands 
CD80/CD86, again they are not considered the key target cells of anti-CTLA-4 
therapy (10). 
 
Overview of B cells in melanoma, in the tumour microenvironment and tertiary 
lymphoid structures 
 
Besides constituting an amalgamation of malignant cells, the tumour 
microenvironment (TME) can be thought of as a distinct complex “organ” which 
contains an array of different cells, such as immune cells, tumour-associated 
vasculature and lymphatics, fibroblasts and pericytes (15). The immune cell infiltrates 
are of special importance as they often correlate with anti-tumour activity and have 
been reported to be associated with a more favourable prognosis in some settings. 
Melanoma is a classically highly immunogenic tumour (19) and lymphocyte infiltrates 
in general have been shown to have positive prognostic value in patients with 
primary cutaneous melanoma (20). Immune cell subsets which are correlated with 
increased patient survival outcome include CD8+ memory T cells, CD4+ T-helper 
cells (21), B cells (22) and NK cells (23). Immune cell infiltrates harbour the potential 
to exert cytotoxic anti-tumour activity, which may be exacerbated by checkpoint 
inhibitor immunotherapy. 
 
Lymphocyte activation typically occurs in secondary lymphoid structures which 
include lymph nodes, the spleen and mucosal-associated lymphoid tissue (24). 
During chronic inflammation, TLS may transiently form, which confer sites enriched 
in B and T lymphocytes and dendritic cells present from disordered compositions to 
more structured and often highly specialised germinal centre-like formations (25). As 
tumours share many of the characteristics of chronic inflammation, it is unsurprising 
that TLS have been identified in a range of cancers adjacent to the tumour site, 
including in 26% of metastatic melanomas (26). Importantly, the presence of TLS has 
been shown to be associated with a more favourable prognosis (27,28) and the 
promotion of immunotherapy response (discussed below) (29). There is compelling 
evidence of ongoing B cell maturation in these sites, driving clonal amplification, 
class switching and somatic hypermutation (SMH). It is therefore clear that 
intralesional B lymphocyte structural organisation and the interaction with other 
lymphocytic cell subsets within TLS could be of particular importance to overall B 
cell-mediated anti-tumour activity. 
 
The majority of melanoma lesions contain significant populations of B cells, usually 
localised within the tumour stroma (one study has reported that 86% of primary 
melanomas harbour at least ten CD20+ stromal B cells per mm2 tumour (30). 
Furthermore, tumour infiltrating B lymphocytes TIL-B in primary lesions make up an 
average of 10% of the total infiltrating lymphocytes (31–33) and can be found 
adjacent to various other immune cell subsets. CD22+ B cells are enriched in 
melanoma lesions compared to healthy skin, and CD20 and CD22 mRNA expression 
is further enhanced with metastasis (34,35), indicating the presence of a pronounced 
humoral immune response in melanoma.  
 
These TIL-B have been shown to contribute to anti-tumour immunity via antibody 
responses to melanoma-associated antigens. In one study, 28% of melanoma 
patient-derived B cell cultures were capable of binding to a wide range of antigens 
expressed by melanoma cell lines, as opposed to just 2% of those derived from 
healthy individuals, and this was shown to further increase with metastatic disease 
(36). In concordance, plasma cells in melanoma lesions were shown to be polyclonal 
and to predominantly express IgG and IgA (37) implicating antigen reactivity and 
class switching, and thus a possible melanoma-reactive B cell immune response. 
Secreted immunoglobulins, especially of the IgG1 subclass, may be able to exert 
potent tumoricidal effects via ADCC, as demonstrated in vitro using a patient-derived 
monoclonal antibody (36). ADCC however is just one of several effector mechanisms 
mediated by secreted immunoglobulin. A neutralising anti-human growth factor 
(HGF) antibody has been shown to suppress tumour growth in vitro (38). B cells may 
also act as antigen presenting cells, contributing to T-helper cell activation and anti-
tumour effector mechanisms (39). Finally, activatory B cells may facilitate anti-tumour 
immunity via the release of pro-inflammatory cytokines such as IL-2, TNFα and IFNγ 
(40,41). TNFα produced by B cells may control the development of follicular dendritic 
cells, the formation of B cell follicles and T cell-dependent antibody responses (42). 
Collectively, several studies therefore support the presence of an antigen-specific B 
cell immune response to melanoma.  
 
In accordance with expectations arising from these anti-tumour properties, the 
percentage of tumour-infiltrating and peritumoral B cells have been found to 
positively correlate with more favourable patient survival in the vast majority of 
melanoma cohort studies (22,43,44). However, some studies have in contrast found 
no significant association between B cell infiltration and overall patient survival (31), 
and even a correlation of B cell infiltrates with a poorer prognosis (33). These 
discrepancies may arise from differences in experimental design and analyses (e.g. 
using raw B cell counts versus percentage of infiltrating populations) or may reflect 
the confounding presence of immunosuppressive regulatory B cells. 
 
 
B cell subsets in melanoma and the role of Bregs 
 
Several studies have demonstrated the enriched presence of various differentiated B 
cell phenotypes such as memory, plasmablasts (PB) and plasma cells within 
melanoma tumours. Elevated percentages of PBs (short-lived cells and part of the 
rapid antigen response) have been reported in the circulation of patients with 
melanoma compared to blood from healthy individuals. PB are short-lived cells and 
part of a rapid antigen response. Although PB have a potentially positive role in 
melanoma, the functional plasticity of these cells may result in transient switching to 
a “regulatory” pro-tumour phenotype owing to expression of TGFβ and IL-10 by this 
cell subset (41). 
 
IL-10-producing “regulatory” B (B10) cells (45) have been shown to be functional in 
murine models of tolerance (46), in preventing chronic inflammation (47–50) and in 
curbing anti-tumour immune responses (51). In mouse models, Bregs appear to be 
derived from either BII (follicular) or Marginal Zone (MZ) cells. A CD1d+ CD19++ 
regulatory B cell subset has been identified in mice which strongly resembles MZ 
cells and protects against colitis, through interactions with Tregs (52). These 
observations not only demonstrate that these cells play a crucial pathogenic role in 
health and disease, but also that B cells can contribute to immune outcomes in 
general via their polarised cytokine expression. 
 
Studies in mouse models of skin cancer suggest that there are certain circumstances 
where B cells can exert a distinctly immunosuppressive pro-tumour effect (53). A 
subset of “tumour-evoked” Bregs has been shown to facilitate the metastasis of 
breast cancer tumours through the induction of Tregs via TGFβ secretion (54). 
Importantly, tumour-associated antigens such as 5-lipoxygenase (breast cancer; (55) 
and placental growth factor (glioblastoma; (56) have been shown to induce IL-10-
production in tumour-infiltrating B cells in murine models. It may therefore be 
possible that B cells in the tumour-microenvironment are coerced into developing a 
regulatory phenotype (TGFβ+ and IL-10+), and that tumour-derived antigens in 
general could induce B cell IL-10-expression (57). As expected, Bregs have been 
shown to directly contribute to tumour-progression as a result of their anti-
inflammatory properties (58). 
 
At present there is a lack of substantial information relating to the role of 
immunosuppressive IL-10-producing B cells in affecting tumour progression in 
humans. Perhaps the most significant study showed that Granzyme-B-expressing IL-
10+ B cells induced by T cells IL-21 secretion infiltrate solid tumours of breast, 
cervical and ovarian cancer patients and inhibit T cell responses (59). In addition, IL-
10+ transitional B cells have been shown to be upregulated in gastric cancer patient 
peripheral blood and tumours and are functionally capable of suppressing Th1 
cytokine secretion by T cells and inducing Tregs (60).  
 
The current evidence for regulatory B cells in melanoma tissue microenvironments 
rests upon a study demonstrating that adoptive transfer of B1a B cells (possessing 
an IL-10+ regulatory phenotype) into wild-type mice significantly exacerbated 
B16F10 melanoma growth, illustrating that IL-10-producing B cells can directly 
contribute to melanoma tumour-progression (61). A separate murine model of 
squamous cell carcinoma obtained similar conclusions (62). Finally, Bregs have been 
shown to supress cutaneous inflammation in a mouse model of psoriasis-like 
inflammation (63). To date, there have been no investigations into the role of IL-10-
producing B cells in patients with melanoma.  
 
Tumour-infiltrating regulatory B cells therefore represent a potential mechanism of 
tumour-mediated immune escape that in certain conditions may outweigh antigen-
presentation and anti-tumour antibody-mediated effector mechanisms to skew the 
overall impact of B cell infiltrates towards a neutral or even a negative effect, and 
mandates studies into the induction of regulatory B cells in melanoma patients and 
correlation with overall survival. 
 
 
Influence of the Th2-biased melanoma microenvironment on pro-tumour 
properties of B cells 
 
Consistent with the contributions of regulatory B cells, the microenvironments of 
melanoma solid tumours are characteristically considered as harbouring Th2-biased 
cytokine expression profiles (64), typical of chronic inflammatory conditions. These 
microenvironments typically confer pro-tumour properties including promoting 
angiogenesis and inhibiting cell-mediated responses, such as those mediated by 
cytotoxic T-lymphocytes (CTLs). The classic Th2 cytokine is interleukin-4 which, in 
addition to interleukin-13, may induce tumour clearance (65). However, IL-10 
produced by Bregs, Tregs and M2-type macrophages in the tumour 
microenvironment can, in addition to its potent suppressive effects upon CTLs, 
trigger a modified or alternative Th2 response by inducing B cell IgG4 subclass 
switching in the presence of IL-4 (66).  
 
Indeed, it has been shown in vitro that these Th2-biased microenvironments favour 
alternatively activated humoral immunity which confers a shift in B cell antibody 
expression towards IgG4 (67). Early evidence has accordingly demonstrated that 
IgG4 serum levels are dysregulated in melanoma patients, particularly in advanced 
disease settings (68). IgG4 subclass antibodies are structurally distinct to IgG1 
antibodies and confer a weaker ability to bind and stimulate effector cells such as 
macrophages to initiate ADCP and ADCC through their Fc-gamma receptors (69). It 
has been shown that these antibodies compete with IgG1 for Fc-gamma receptor 
sites resulting in a reduced degree of immune cell activation and tumour-cell killing 
when secreted in large quantities (34,67). Recent evidence also suggests that Fc-Fc 
interactions between IgG4 and cancer-specific IgG1 antibodies may confer an 
important aspect of tumour immune evasion (70). Interestingly, the same study also 
demonstrated that the IgG4 subclass CPI antibody Nivolumab participated in Fc-
interactions with IgG1 subclasses and promoted cancer growth in a murine model of 
colon cancer. The pro-tumour role of IgG4 subclasses may appropriately explain 
observations of possible hyperprogressive disease seen in some CPI patients.  
 
IgG4 is therefore a negative prognostic indicator of patient overall survival, and these 
Th2 biased microenvironments offer a form of immune evasion which is mediated by 
IL-10 (71,72). Interestingly, recent evidence has also revealed that an IgG4-
expressing CD49b+ CD73+ B cell subset expressing proangiogenic cytokines 
including VEGF is upregulated in the circulation of melanoma patients, highlighting 
an additional and previously unknown mechanism by which tumour-infiltrating B cells 
may contribute to tumour progression (73) . 
 
 
The role of B cells in checkpoint inhibitor therapy responses 
 
Checkpoint inhibitors are designed to regulate T cell effector functions, however 
there is growing interest in the contribution of B cell responses to patient outcomes. 
This has been examined in several recent studies, the findings are summarised in 
Table 1 and Figure 2.  
 
Tumour-infiltrating B cell signatures in relation to CPI treatment response:  
Further evidence supports the notion that specific B cell subsets may hold prognostic 
value in CPI treatment response in advanced melanoma. B cell receptor repertoire 
and B cell phenotype were analysed in 473 cutaneous melanoma specimens. The 
absence of B cell immunoglobulin heavy chain γ (IGHG) gene was found to correlate 
with lack of response to anti-CTLA-4 but this was not shown in the context of anti-
PD-1 therapy (22). In addition, a higher proportion of IL-10 secreting B cells was 
associated with lack of response to anti-CTLA-4, but was not correlated with 
response to anti-PD-1 therapy (22). A phase 2 trial of neoadjuvant CPI (neoadjuvant 
Nivolumab (n=11) versus neoadjuvant Nivolumab plus Ipilimumab (n=12)) (74) also 
highlighted the importance of B cells in CPI response. While baseline tumour-
infiltrating B cell counts did not differ significantly between responders and non-
responders in this small sample size, early on-treatment tumour samples showed 
increased tumour-infiltrating B cell frequency (as defined by CD20 immunostaining) 
in treatment responders compared with non-responders. Helmink et al. used the 
same cohort and performed bulk RNA sequencing from baseline and early on-
treatment tumour biopsy samples (75) and found that B cell markers were the most 
differentially expressed genes in responders to therapy compared with non-
responders. They identified significantly increased clonal counts for both 
immunoglobulin heavy and light chains and increased BCR diversity in responders 
than in non-responders, which suggests an active role for B cells in anti-tumour 
immunity. Pathways upregulated in responders as compared to non-responders 
included those consistent with increased immune activity such as CXCR4 signalling, 
cytokine receptor interaction and chemokine signalling pathways. Phenotyping of B 
cells in tumours identified significantly higher frequency of memory B cells in 
responders versus non-responders at baseline and early on-treatment. They 
corroborated their findings in a further cohort of 18 patients with melanoma treated 
with adjuvant or neoadjuvant CPI. Unlike tumour-derived B cells, a peripheral blood 
B cell phenotype was not found to correlate with treatment outcome (75). Since most 
samples in this study were blood or metastatic lymph node deposits, the cohort was 
relatively small and the samples were sourced either at baseline or early on-
treatment, these findings would benefit from evaluations of larger and more 
comprehensive studies.  
 
Furthermore, in a cohort of 39 patients with advanced melanoma, early changes 
were observed in peripheral B cell subsets upon one cycle of combination CPI 
therapy (Ipilimumab and Nivolumab): particularly a significant decrease in circulating 
B cells in patients who underwent combination CPI as opposed to those treated with 
a monotherapy anti-CLTA-4 or anti-PD-1 (76). No significant differences were found 
between naïve and memory B cell subpopulations. Despite the overall decline in B 
cell numbers, a marked increase was observed in the density of: class-switched 
memory B cells, plasmablasts and CD21lo B cell sub-populations (76). Of note, 
significant changes in the latter were only exhibited in patients who underwent 
combination or anti-CTLA-4 treatment. This is consistent with findings from a 
previous study whereby, loss of circulating B cells and increase in CD21lo B cells was 
reported in patients treated with an anti-CTLA-4 agent (77). Detailed evaluation of 
the CD21lo B cell compartment revealed equal concentrations of naïve and memory 
B cells at baseline, but moderate increase in memory B cells after combination 
checkpoint inhibition. Furthermore, B cell receptor sequencing demonstrated that 
CD21lo B cells possessed higher: clonality, maximal clone frequency, and SHM 
frequency. Therefore, CD21lo B cells were shown as a phenotypically distinct B cell 
subset present in melanoma patients, which increased in frequency following 
combination checkpoint inhibition, and suggest an active B cell response in the TME. 
PD-1 expression on the CD21lo B cells was higher than on other B cell subsets, 
suggesting that this population may be specifically modulated by anti-PD-1 therapy. 
This study failed to find an association between B cell changes and clinical response. 
The extrapolation of these findings may be limited due to the small sample size and 
the fact that on-treatment peripheral blood samples were only taken at an early time 
point after commencement of CPI therefore may not be representative of the full 
response.  
 
CPI-associated modulation of plasmablasts: 
There is some evidence that plasmablasts (PB) may be directly modulated by CPI. 
Circulating plasmablast levels were significantly enhanced in patients undergoing 
treatment with anti-CTLA-4 immunotherapy (78). When immunoglobulins produced 
by the PBs were sequenced, there was evidence of clonal expansion, SMH and 
class switching, indicative of an active B cell response (78). Immunostaining of 41 
metastatic melanoma specimens revealed that a plasmablast-like phenotype 
(CD19+CD20+CD38+CD138-) is the most frequently observed B cell subset in the 
TME (41). Furthermore, circulating B cells could be induced to differentiate into 
plasmablast-like cells when exposed to autologous melanoma secretomes in vitro 
(41). In this study tumour-associated B-cells also expressed T-cell and macrophage 
chemoattractant mediators (CCL3, CCL3L1, CCL4, CCL5, CCL28, and CXCL16) 
suggesting that B-cells can orchestrate the immune response in the TME by 
modulating other cell populations. Increased expression of immunosuppressive 
cytokines IL-10 and TGFβ1 was reported in plasmablast-like and memory B cell 
subpopulations, consistent with a potential regulatory role. However, these 
signatures may also be associated with treatment response: proteomics and RNA-
seq data were used to define a tumour-induced plasmablast-like population (TIBP) 
functional signature and this signature was evaluated in a historical dataset from 
patients treated with Nivolumab. In this analysis, the presence of this TIBP signature 
at baseline correlated with better response to anti-PD-1 treatment (41).  
 
A role for tertiary lymphoid structures: 
The importance of TLS in response to CPI has also been investigated. Helmink et al. 
delved deeper into the localisation of B cells within their original cohort of 23 tumours 
and identified a higher density of CD20+ B cells in TLS and a higher TLS:tumour 
area ratio in early on-treatment samples from responders versus biopsies from non-
responders (75). They also illustrated that CD20 B cells often co-localised with CD4, 
CD8 and FOXP3 T cells. A second study also identified CD20 B cells in 25% of 177 
melanoma specimens (27). CD20 B cell clusters were surrounded by CD4 T cells. 
Increased expression of known molecular markers of TLS (CXCL13, CXCR5 and 
DC-LAMP) was described and immunostaining confirmed the co-localisation of 
CXCL13 and CXCR5 with the CD20 B cell marker. A TLS gene signature in 
melanoma was defined and integrated into four historical melanoma cohorts treated 
with CPI. This TLS gene signature at baseline was associated with significantly-
increased survival with anti-CTLA-4 therapy and this was independent of the tumour 
mutational burden which may be a predictor for TLS formation (27). The role of B 
cells in TLS in response to CPI has also been highlighted in a third study in the 
treatment of sarcoma (79). In this, 213 soft tissue sarcomas were stratified according 
to the composition of the TME. Those with highest density of B cells and TLSs were 
associated with the highest response rate to CPI. The study identified several 
immune cell-related gene signatures and the only one significantly associated with 
extended overall survival was the B cell signature (79).  
 
Taken together these studies highlight that B cell phenotype, localization with TLS 
and B cell gene expression may be directly modulated by CPI and could be relevant 
to treatment outcomes. The differential results seen with different agents and 




Antibody responses in melanoma  
 
A key feature of B cells is their ability to produce antibodies. B cells in the tumour can 
undergo class switching and affinity maturation, producing tumour-specific or non-
specific antibodies of different isotypes (24) and could exert anti-tumour or pro-
tumour roles (81). Human antibodies are tetrameric glycoproteins formed by two 
heavy and two light polypeptide chains. Heavy and light chains assemble in a Y 
shaped structure, defined by a Fab region (formed by two identical Fab fragments, 
composed by the light chain and part of the heavy chain), an Fc region (formed by 
the constant portion of the two heavy chains) and a hinge region (joining Fab and Fc 
regions). The variable regions of heavy and light chains are assembled to form two 
identical antigen binding sites. The heavy chain constant region determines the 
isotype of the antibody, with a characteristic hinge and Fc region. The hinge region is 
responsible for the flexibility of the Fab arms which can affect both antigen binding 
and effector function and for some isotypes, such as IgG4, these can be involved in a 
process called Fab Arm Exchange, which results in bispecific (IgG4) antibodies (72). 
The Fc region is involved in the binding to Fc receptors (FcRs) and C1q 
(complement) and is responsible for antibody mediated effector functions such as 
ADCC, ADCP and CDC (80).  
 
Depending on their isotype and specificity, antibodies can have opposite roles in the 
tumour associated immune response. Different antibody isotypes have different 
affinity for FcRs and C1q and consequently have different ability to trigger effector 
functions. Tumour specific antibodies with high affinity for FcRs and C1q (such as 
IgG1) have the potential to engender anti-tumour effects, mediating ADCC, ADCP, 
CDC or to support antigen presentation by mediating the uptake of tumour antigens 
by APCs such as macrophages and dendritic cells (82). Furthermore, membrane 
bound tumour-specific antibodies on the surface of B cells can engage with tumour 
cells and trigger B cell mediated cytotoxicity. Evidence of B cell mediated cytotoxicity 
via granzyme B and TRAIL has been shown in hepatocellular carcinoma (83). IgG 
class antibodies have been found to be tumour-specific, and this has been reported 
in melanoma (84) and other cancer types and has been correlated with a favourable 
prognosis (85–88). 
 
Tumour associated antibodies can also have either pro-tumour effects or their anti-
tumour effects may be regulated by tumours. Tumour-specific antibody-mediated 
immune cell activation and anti-tumour cytotoxicity may also be impaired by 
expression of inhibitory Fc receptors (FcγRIIb) in the TME and downstream 
immunoreceptor tyrosine-based inhibitory motif (ITIM) domain signalling (89,90). 
Tumour-specific antibodies may be expressed as isotypes (such as IgG2 or IgG4) 
with poor affinity for activating FcRs or complement. These isotypes can be 
ineffective in triggering anti-tumour responses like ADCC, ADCP, CDC and antigen 
presentation (72). Furthermore, IgG4 antibodies can engage the inhibitory receptor 
FcγRIIb. This might further impair anti-tumour responses, blocking IgG1 mediated 
effector function (67). Tumour associated antibodies not specific for the tumour can 
also serve as a decoy blocking other potentially immuno-activating and tumour-
reactive antibodies from engaging with immune effector cells. This can contribute to 
pro-tumour effects such as ineffective T cell mediated responses or B effector 
functions. It is also possible that tumour-specific antibodies accumulating at the 
tumour site over time forming immune-complexes, promoting chronic inflammation 
and immunosuppressive myeloid cell phenotypes (82).  
 
Isotypes like IgG1 and IgG3 have high capacity to trigger ADCC and facilitate 
complement activation. The IgG1 isotype is usually associated with anti-tumour 
responses while TCGA RNA-seq data analysis of melanoma samples showed that 
IgG3 is either neutral or is associated with a negative prognosis. This could be 
explained by the fact that IgG3 has a shorter half-life (1 week) compared to other 
isotypes (IgG1, 2 weeks). Furthermore B cells expressing IgG3 isotype antibodies 
usually undergo less antibody SHM and therefore IgG3 antibodies may have lower 
affinity for the target antigen whilst still able to occupy FcRs (91). IgG2 has poor 
ability to bind FcRs and C1q. Evidence of antibody responses switched to IgG2 has 
been found in melanoma (26). IgG4 has poor ability to bind activating FcRs whilst 
able to bind the inhibitory receptor FcγRIIb and has complement-activating ability. 
Evidence of IgG4 antibody responses have been found in the melanoma TME and 
serum IgG4 has been associated with poor prognosis in melanoma (36,67,71).  
 
TCGA RNA-seq data analyses also suggest that IgD, IgE and IgA antibodies may be 
associated with poor prognosis in melanoma (91). One possible explanation is that 
IgD can bind basophils resulting in the production of cytokines like IL-4, IL-5, IL-13, 
BAFF and APRIL which may support class switching to IgA and IgE and a Th2 
immune response. Furthermore, the presence of IgE antibodies is usually associated 
with IL-4, which can further support a Th2 immune response. IgA antibodies have 
been found in melanoma and are associated with poor prognosis. This could be 
explained by the immune-suppressive phenotype of IgA+ B cells, expressing IL-10 
and PD-L1 and by the ability of IgA+ B cells to support the expansion of T regulatory 
(Treg) cells which in turn secrete TGFβ supporting IgA class switch. Melanoma-
associated IgA have been found to correlate with poor clonality, suggesting that, in 
the tumour, class switching to IgA is a consequence of inflammation and not of an 
antigen-driven response, and that tumour associated IgA could be non-tumour 
specific (82).  
 
 
Associations of B cell expressed antibodies with CPI treatment 
 
Based on mounting evidence in support of potential roles of various antibody 
isotypes in melanoma, it is not surprising that antibody responses have been studied 
and are thought to correlate with outcome of CPI therapy. In the context of B cells in 
HIV infection, blocking of PD-1 has been shown to increase viral antigen-specific 
antibody responses (92). This may lend merit to the notion that PD-1-specific CPI 
could improve tumour-specific antibody responses (93). 
 
One study investigated whether IgG antibody and isotype levels correlated with anti-
tumour response and survival following CPI therapy. IgG subclass analysis was 
performed on serum samples at baseline from 49 patients with melanoma treated 
with anti-PD1 antibody (Nivolumab or Pembrolizumab (86%), Nivolumab plus 
Ipilimumab (10%), or Ipilimumab (4%). A positive correlation with progression-free 
survival (PFS) was found for high titres of total IgG, IgG1, IgG2 and IgG3, while a 
positive correlation with overall survival (OS) was found to be significant only for the 
IgG2 subclass (94). This result is quite interesting since IgG2 is usually not 
associated with anti-tumour immune responses due to its poor ability to trigger 
ADCC, ADCP, CDC and facilitate antigen presentation, but may reflect activation of a 
tumour antigen-specific response triggered by CPI. 
 
A different preliminary study compared the antibody sequence repertoires of 26 
patients with melanoma treated with Pembrolizumab (9), Ipilimumab (8) or 
Nivolumab and Ipilimumab combination (9). It was found that long-term responders 
had higher levels of SHM after initiation of treatment, and on-treatment compared to 
the non-responders. Comparison of lineages between patients identified antibodies 
with high sequence similarity suggesting these antibodies may have arisen from 
convergent selection, i.e., different patients raising antibodies against shared or 
similar epitopes. Moreover, when antibody lineages were analysed and compared 
among patients, antibodies with high sequence similarity were found, suggesting 
these antibodies may have arisen from convergent selection and that the patients 
may be producing antibodies against shared epitopes. Of note, IgG2 was the most 
frequent isotype of these antibodies. Furthermore IgG2 was higher in responders 
compared to non-responders (95).  
 
In a different study, melanoma patients treated with CPI (monotherapy with 
Nivolumab, Pembrolizumab or Ipilimumab, or the combination of Nivolumab and 
Ipilimumab), the responder group had higher titres of antibodies specific for the 
tumour associated antigens MDA (TRP1/TYRP1, TRP2/TYRP2, gp100, 
MelanA/MART1) and the Cancer-Testis antigen NY-ESO-1 at baseline, compared to 
non-responders. Serum analyses showed that NY-ESO-1, TRP1/TYRP1 and 
TRP2/TYRP2 specific antibodies consisted of several IgG subclasses while the IgG 
antibodies for MelanA were mostly IgG1 and the antibodies for gp100 were of the 
IgG2 isotype (84). Interestingly, none of these antibodies were IgG4, supporting the 
fact that IgG4 antibodies are not associated with a good prognosis in melanoma 
patients (67,71,84,94).  
 
In patients with metastatic melanoma who were treated with anti-CTLA-4 combined 
with anti-angiogenic VEGF-A-targeted treatment, there was an increase of antibody 
titres recognising the immunoregulatory protein Galectin-1 (Gal-1). Anti-Gal-1 
antibody titres in turn correlated with better disease outcome. Higher frequencies of 
complete or partial responses and improved overall survival were seen in these 
individuals. Gal-1 has been reported to be upregulated in many tumour types 
including melanoma and is usually associated with poorer survival, contributing to 
tumour growth, angiogenesis, metastasis and immune evasion (96). 
 
Taken together, these results suggest that checkpoint blockade-associated 
restoration of T cell activity may also contribute to increasing the effectiveness of the 
humoral response and highlights the importance of the expressed antibodies as part 
of the anti-tumour activity. Furthermore, these studies suggest that melanoma-
specific antibodies in pre-treatment sera may be promising indicators of CPI 
immunotherapy response and require further study.   
 
 
Correlations with immune related adverse events in CPI therapy 
 
Activation of immune responses as a result of checkpoint inhibition can lead to 
compromised immune self-tolerance and can consequently result in the development 
of irAEs, toxicities that mimic autoimmunity. The nature and frequency of irAEs varies 
amongst CPI agents and can include effects on the gastrointestinal tract (colitis), liver 
(hepatitis), lung (pneumonitis) and endocrine systems, including hypophysitis and 
insulin-dependent diabetes. The effects of anti-CTLA4 associated irAEs are generally 
more severe than those from anti PD-1 inhibition. Whether irAEs represent de novo 
events or whether they represent an unmasking of underlying immune mediated 
disease remains unclear (6).  
 
Modulation of B cell phenotype has been correlated with irAE in patients undergoing 
CPI therapy. A recent study (described above) demonstrated an overall decline in B 
cell numbers but increased plasmablasts and CD21lo B cell subsets in patients given 
combination checkpoint inhibition (Table 1) (76). These CPI induced B cell changes 
positively correlated with frequency and severity of irAEs. Furthermore, patients with 
altered B cell populations were more likely to develop multi-organ immunotoxicity 
than those without, with these changes preceding toxicity by a median of 3 weeks.  
  
B cells are proposed to contribute to autoimmunity via multiple mechanisms including 
as antibody secreting cells, cytokine producers, APCs and immunoregulators. Given 
the important role of the checkpoint pathways in regulating immune homeostasis, it is 
not surprising that activation of the CTLA-4 pathway has been extensively studied in 
the treatment of autoimmunity. Specifically Abatecept, a fusion protein of CTLA-4 
and IgG1 Fc portion (CTLA-4-Ig), is approved for abrogating immune overactivity in 
rheumatoid arthritis (97–99). CTLA-4-Ig is able to directly bind CD80/86; therefore, 
preventing CD28 binding and T cell co-stimulation. B cells are known to express 
CD80/86 and have been shown in mouse models and in vitro to be a direct target for 
CTLA-Ig. In synovial biopsy samples, CTLA-4-Ig has been shown to decrease B cell 
infiltrates (97). Humoral responses to T cell dependent and T cell independent 
antigenic stimulation are also suppressed by CTLA-4-Ig in vivo (100,101). These 
insights from autoimmunity may also have relevance to our understanding of how 
CPI modification of B cells may induce irAE.  
 
The presence of autoantibodies in CPI induced irAE has been detected in a similar 
fashion to those seen in autoimmune disease in the absence CPI treatment. For 
example some patients suffering with CPI-induced hypothyroidism have raised titres 
of anti-thyroperoxidase antibody and/or anti-thyrotropin receptor antibodies 
(102,103). However, as these autoantibodies are not universally detected in CPI 
thyroid disorders it is unclear whether they play a causative role. Similar observations 
have been made in a range of CPI induced autoimmune phenomena including cases 
of myasthenia gravis (104), type 1 diabetes mellitus (105) and autoimmune 
haemolytic anaemia (106). One study analysed 23 common autoantibodies in 
baseline peripheral blood and post CPI treatment in 133 melanoma patients treated 
with Ipilimumab (107). This showed that 19% of patients developed autoantibodies 
on-treatment and a trend of association with onset of irAE which did not reach 
statistical significance. In this study, organ-specific autoantibodies did not correlate 
with irAE.  
 
CPI induced irAE present a clinical challenge for patient selection and can lead to 
treatment discontinuation. Insights into the complex balance between activation and 
suppression of B cell subsets may infer consequences for both treatment response 
and irAE. In addition, the potential contributions of autoantibodies to irAE warrant 




Harnessing the humoral immune response in melanoma immunotherapy 
 
Data from several studies suggest that B cells can play multi-faceted roles in the 
immune response to melanoma and that melanoma-associated immune evasion 
mechanisms involve modulating B cell immunity in addition to suppressing T cell 
activation. Despite the impressive efficacy demonstrated by CPI, a large proportion 
of patients fail to respond and/or develop irAEs (4,103-104). Modulated B cell and 
antibody repertoires could either obstruct or facilitate the efficacy of CPI, depending 
on an array of factors in the TME. Further research identifying specific cellular 
surface markers and methods to clearly dissect the various B cell phenotypes will 
help improve our understanding of B cell immunity in melanoma and whether and 
how this is altered by CPI. This may then be exploited in clinical trials to help identify 
therapeutic strategies which can be combined with CPI to improve response. This 
may include the targeting of B cells; a pilot study using Rituximab (anti-CD20) to 
deplete B cells in melanoma patients increased the median time without recurrence 
from 6 to 42 months (110). On the other hand, B cell depletion therapy may have 
contrasting effects dependent on the stage of melanoma in mouse models (41). 
Given the newfound appreciation of the complexity of the TIL-B subpopulations, a 
more effective approach may involve depleting specific pro-tumour subsets, such as 
Bregs and IL-10+ B cells, whilst promoting anti-tumour subsets which could be 
combined with CPI as an adjuvant (24). PD1-PD-L1 engagement plays a role in 
suppressing B cell-mediated T cell activation, influencing CPI efficacy. Inhibition of 
PD-1 expressed on B cells may also be a mechanism through which CPI directly 
modulate B cell responses.  
 
The targeting of the immunosuppressive TME cytokines IL-10, VEGF or TGF-ß may 
effectively reinstate robust anti-tumour immunity by preventing IgG1 to IgG4 class 
switching and promoting anti-tumour B cell subsets to engage in tumour rejection. 
The hostile TME may be taken into consideration in the engineering of therapeutic 
antibody candidates, with the aim of potentially producing antibodies more resilient to 
immune suppression. CPI antibodies could additionally be engineered to have 
reduced binding to inhibitory Fc receptors, increased binding to activatory Fc 
receptors, or consider alternative isotypes such as IgE which has been implicated to 
improve immune surveillance in melanoma (111–113). 
 
Aside from clinical response, irAEs are a major challenge of CPI in melanoma, as 
96% of patients receiving combined CPI experienced at least one irAE in the 
CheckMate067 trial (4). Immune monitoring for early alterations in B cells following 
CPI may hold some promise in determining those at risk of developing irAEs. If 
confirmed to contribute to irAEs, therapies targeting plasmablasts and CD21lo B cells 
could be explored to reduce the risk. Serum and melanoma IgG4 and IgG4+ B cell 
levels may also be monitored and therapies targeting these subsets could be 
conducted prior to CPI to establish a ‘hot’ tumour more likely to respond to CPI. 
Throughout CPI, B cell and antibody levels may be monitored to determine 
modulation and predict prognostic outcomes and spikes may be countered through 
further depletion methods. Similar strategies could be conducted with 






It is increasingly appreciated that melanoma can develop intricate mechanisms to 
modulate the humoral immune response and B cell immunity may also play a 
significant role in the efficacy and safety of CPI in melanoma. Taking all into 
consideration, it is highly conceivable that the promotion of anti-tumour B cell 
immunity with targeted therapies can also have clinical relevance in CPI response. 
Furthermore, immunomonitoring of humoral responses prior to, during and following 
CPI in predicting irAEs should be explored. Given the complexity of tumour:immune 
cross-talk, utilising B cells and antibodies as prognostic/predictive biomarkers, in 
patient stratification and in immunomonitoring remains largely unexplored. Factoring 
in B cell immunity may harbour significant potential to overcome the two greatest 
challenges associated with CPI in melanoma: response and irAEs. Further studies in 
patients, in vivo and ex vivo models of immuno-oncology, alongside clinical testing, 
are required to fully comprehend and exploit likely multifaceted contributions.   
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Table 1: Summary of current evidence of a humoral immune response in 






CPI used Target B cell and antibody responses Reference 
Tumour Baseline Ipilimumab CTLA-4 ▪ IL10+ Breg enrichment found in 
non-responders to anti-CTLA-4 
therapy  
▪ Absence of IGHG gene signature 
enriched in non-responders to 
anti-CTLA-4 
(22) 
Nivolumab PD-1 ▪ IL10+ Breg presence did not 
correlate with treatment response 
to anti-PD-1 
▪ IGHG gene signature did not 









▪ For all treatments increased B 
cell frequency found in the 
tumours of responders to both 
combination therapy and anti-PD-
1 monotherapy in both baseline 
and early on treatment samples 
▪ For all treatments higher density 
of CD20+ B cells and TLS and a 
higher TLS:tumour area ratio in 
early on-treatment samples from 
responders versus non-
responders 
▪ For all treatments increased 
frequency of switched memory B 
cells found in responders at 










Nivolumab  PD-1 
Tumour Baseline Ipilimumab 
 
 
CTLA-4 ▪ B cells found to localise within 
TLS 
▪ TLS gene signature present in 
responders’’ 
▪ TLS structures associated with 
CD8+ T cells 
(114) 
Periphera




treatment     
Ipilimumab CTLA-4 ▪ High plasmablast numbers seen 
in patients responding to anti-
CTLA-4  
▪ Sequenced plasmablast 
antibodies in patients who had 
not progressed after 1 year had 
somatic hypermutation, class 
switching and clonal expansion 





Baseline Nivolumab PD-1 ▪ Plasmablast-like phenotype 
(CD19+CD20+CD38+CD138-) 
found to be most common B cell 
phenotype in TME  
▪ Tumour induced plasmablast 
population (TIBP) defined using 
melanoma secretome 
▪ Increased expression of TIPB 
gene signature in baseline 





improved response to Nivolumab 
Periphera
l blood  
Baseline Nivolumab PD-1 ▪ Melanoma-antigen specific 
antibodies to: MDA 
(TRP1/TYRP1, TRP2/TYRP2, 
gp100, MelanA/MART1) and the 
Cancer-Testis antigen NY-ESO-1 
higher in responders to all 
treatments  
▪ Melanoma-antigen specific IgGs 
higher in responders at baseline 
compared with non-responders 
for all treatments  
▪ Melanoma-antigen specific IgGs 
















l blood  
Baseline Nivolumab PD-1 ▪ For all treatments high titres of 
IgG, IgG1, IgG2 and IgG3 
showed a positive correlation 
with progression-free survival 
(PFS) 
▪ For all treatments high titre of 
IgG2 showed a positive 
correlation with overall survival 
(OS)  













l blood  







▪ Overall decline in B cell numbers 
but increased plasmablast and 
CD21lo B cell subsets 
corresponded to development of 
high grade immune related 
adverse events (irAE) 
▪ Changes in other immune cells 
not significantly associated with 







Figure 1 Proposed humoral responses in cancer and in response to checkpoint 
inhibitor immunotherapy.  
Putative pro- and anti-tumour roles of B cells in the tumour microenvironment (TME) 
and tumour tertiary lymphoid structures (TLS). B cells may confer several anti-tumour 
roles through production of effective tumour-clearing antibodies, predominantly IgG1: 
mediating antibody dependent cell-mediated cytotoxicity (ADCC), antibody 
dependent cell-mediated phagocytosis (ADCP) and facilitating complement 
activation. B cells can also effectively modulate CD4 and CD8 T cells via their 
functions as antigen presenting cells (APCs) to present tumour-derived antigens or 
by promoting cytokine secretion, particularly IFNγ and IL-2 by T cells. B cells can 
also support the presentation of tumour-derived antigens by other antigen presenting 
cells including macrophages and dendritic cells. Antigen presentation and B cell 
activation may be enhanced in TLS, leading to somatic hypermutation, clonal 
amplification and isotype switching to activatory antibody isotypes such as IgG1, 
further driving anti-tumour responses. B cells can also directly exert cytotoxic 
functions against tumour cells (e.g. through secretion of granzyme B). B cells can 
have pro-tumour roles by multiple mechanisms, for instance through expression of 
inflammatory antibody isotypes such as IgG4. IL-10 producing regulatory B cell 
(Breg) phenotype is described which can negatively modulate the function of effector 
CD8 T cells, induce the development of regulatory T cells (Tregs) and dampen the 
activity of antigen-presenting cells such as dendritic cells and macrophages. IgA 
producing regulatory B cells have also been described in the TME.  
 
Figure 2 Proposed B cell features at baseline that predict response to 
checkpoint inhibitor treatment.  
B cell phenotypes enriched in tumours and the circulation of patients before 
treatment may be predictive of clinical response to checkpoint inhibitor therapy. 
Features include the presence of memory B cells (e.g. Ipilimumab monotherapy and 
combination of Ipilimumab and Nivolumab) and plasmablasts (e.g. Ipilimumab and 
Nivolumab monotherapies). In the peripheral blood, immunoglobulin isotypes IgG1, 
IgG2 and IgG3 have been associated with response to Ipilimumab and Nivolumab 
monotherapies. Melanoma-antigen specific IgG antibodies have been found to be 
increased in responders to therapy (monotherapy with Ipilimumab, Pembrolizumab 
and Nivolumab; as well as with combination of Ipilimumab and Nivolumab). 
Conversely, enrichment of tumours with IL10+ regulatory B cells and an absence of 
an IGHG gene signature has been associated with a poor response to Ipilimumab. 
FcγR: Fcγ receptor; NK: natural killer; TCR: T cell receptor. 
  
 
 
 
 
 
 
 
